Used primarily in pharmaceutical research as a potent and selective inhibitor of phosphodiesterase 10A (PDE10A), this compound is investigated for its potential in treating central nervous system disorders, particularly schizophrenia and other psychiatric conditions involving psychosis. By modulating PDE10A activity, it influences cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling pathways in the brain, which are critical in regulating cognitive function and behavior. It has shown efficacy in preclinical models for improving cognitive deficits and reducing positive symptoms of schizophrenia without inducing motor side effects commonly associated with antipsychotics. Its application remains mainly in early-stage drug development and target validation studies.